Hellman and Weichselbaum first proposed a clinically significant state of oligometastasis in 1995 (REF. 1). With data available at the time suggesting a stepwise progres sion of malignancy, the authors posited that tumours that are early in their chain of progression could result in an intermediate state of cancer spread between local ized disease and widespread metastases 2, 3 . The practical significance of the oligometastatic paradigm was the implication that some patients in this state could be cured with definitive directed therapies 4, 5 . Over the past two decades, our understanding of the oligometastatic state has continued to mature 6 . Meanwhile, oligometastatic disease is increasingly diag nosed -possibly owing to closer patient monitoring in the setting of clinical trials, improved detection of limi ted disease states with advanced imaging, and emerging therapies that have prolonged survival with a diagnosis of cancer 7, 8 . At the same time, emerging genomic data have suggested distinct biological differences between limited metastatic lesions and widely disseminated disease for multiple primary cancers, including that of the prostate [9] [10] [11] . Such preliminary findings support the possibility of a true oligometastatic biology, distinct from one in which clinically apparent lesions are simply initial manifestations of a more widespread process. The ability to distinguish these disease states is crucial when considering an aggressive treatment approach in the population of patients with metastatic prostate cancer 12 .
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At the same time, the paradigm for treatment of advanced prostate cancer is undergoing dramatic change 13 . Traditionally, local therapies such as radical prostatectomy and radiotherapy were offered only with the intention to cure localized disease 14 and evidence of metastasis -even minimal disease such as a single positive pelvic lymph node -precluded an aggressive thera peutic approach. Such men were instead treated with systemic therapies such as androgen deprivation therapy (ADT) 15, 16 . However, emerging data suggest that treatment of the primary tumour might provide a survival benefit to men with metastatic and lymph node positive disease [17] [18] [19] [20] [21] . Similar observations have been made in treatment of metastatic lesions with life prolonging, rather than palliative, intent 22 . Indeed, inter est in the treatment of oligometastatic prostate cancer is greater than ever before.
Treatment of oligometastatic prostate cancer is com plicated by the lack of uniformity in describing the con dition. Traditional definitions of oligometastatic disease Abstract | The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.
have been based on the number of lesions detected by bone scan, with additional classification based on the anatomical sites of the disease. Even so, such definitions vary widely throughout the literature. Furthermore, dif ferentiating between synchronous disease -in which the prostate is untreated (de novo or primary metas tases) -and metachronous disease, in which the pri mary tumour was previously treated and metastases are encountered during recurrence (recurrent oligome tastases), is essential. Although primary and recurrent oligometastatic disease are likely to represent distinct biological states -a fact that should be considered when initiating systemic therapies -the effect of this distinction on sitedirected therapies is unclear. With these points in mind, commonly used definitions of oligometastatic prostate cancer based on contemporary reports and active clinical trials require assessment.
The curative treatment of oligometastatic prostate cancer is likely to require a threetiered approach: firstly, local consolidative therapy of the primary tumour, sec ondly, metastasisdirected therapy, and thirdly, systemic chemohormonal therapy. Questions persist regarding the optimal timing and duration of ADT, but it remains a cornerstone of systemic therapy 23, 24 , and several large prospective clinical trials have been directed at optimiz ing the use of chemotherapy 25, 26 . By contrast, limited data are available that explore local and metastasisdirected interventions with nonpalliative (that is, curative) intent. These data are uniformly retrospective and subject to substantial biases, particularly that of treatment selec tion. These and other limitations must be noted when considering such studies. Furthermore, as many reports of local treatment did not differentiate oligometastatic from polymetastatic disease, a portion of these data are derived from heterogeneous populations. This limita tion is unlikely to influence safety outcomes, but would presumably affect diseasespecific survival data. Indeed, the authors of such studies acknowledge that limitations pervade the literature. Thus, the goal of this Review is not to establish expected rates of diseasespecific outcomes within this patient population, but rather to generally assess whether treatment seems safe and beneficial in what is a poorly characterized setting.
Studies defining oligometastatic prostate cancer
Six original articles and ten prospective trials have expli citly defined oligometastatic prostate cancer [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (TABLE 1) .
Oligometastatic prostate cancer was defined based on the number of detectable lesions in all six original reports. Two articles (33%) limited inclusion to five or fewer metastases, one article (27%) to four or fewer, and three articles (50%) to three or fewer. Tabata et al. 27 included only bony metastases in which lesions were less than 50% of the size of a vertebral body, according to extent of dis ease criteria previously described by Soloway and col leagues 43 . Two studies limited inclusion to bone or lymph node metastases. Three reports did not define oligome tastasis based on site. In five of the six original reports, detection of lesions was most commonly performed using 18 Ffluorodeoxyglucose (FDG) or 11 Ccholine PET with coregistered Xray CT. One study did not specify the imaging modalities used for lesion detection.
Nine of 10 (90%) active clinical trials explicitly limi ted the number of metastases included [34] [35] [36] [37] [38] [39] [40] [41] [42] . Similar to published reports, the majority of trials included up to three (n = 3, 30%) 36,38,42 , four (n = 2, 20%) 35,37 , or five (n = 3, 30%) 34,39,40 metastatic lesions, while one trial (10%) included up to ten 41 . One centre limited the number of lesions to five, but specified that no more than three tumours could be present in a given organ system. The sites of metastases were not specified in two trials 36, 39 and were only specified as extrapelvic in two trials 34, 35 . Similar to retrospective reports, bone and lymph node metastases were commonly outlined when sitespecific criteria were utilized.
Local consolidative therapy
Six contemporary reports of local consolidative therapy for metastatic prostate cancer are available in the litera ture [44] [45] [46] [47] [48] [49] (TABLE 2) 45 subsequently assessed the SEER popu lation using alternative methodology. To ensure that observed effects were attributable to treatment rather than baseline cohort differences 50 , the authors performed propensity score analysis considering age, race, marital status, tumour grade, serum PSA level, and cancer registry. Notably, these authors observed decreased CSM after radical prostatectomy or brachytherapy regardless of the extent of metastatic disease. For example, relative to the no local therapy group, the adjusted hazard ratios associated with radical prostatectomy were 0.18 (95% CI 0.07-0.50, P = 0.0008), 0.22 (95% CI 0.16-0.30, P < 0.0001), and 0.23 (95% CI 0.16-0.35, P < 0.0001) for M1a (metastasis of non regional lymph nodes), M1b, and M1c disease, respec tively. Corresponding values in the brachytherapy C-choline PET-CT (n = 7), MRI (n = 6), biopsy (n = 1), CT (n = 1), 11 C-choline PET-CT and MRI (n = 2)
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Bone or LN • Bone scan + cohort were 0.29 (95% CI 0.13-0.64, P = 0.0024), 0.49 (0.36-0.67, P <0.0001), and 0.36 (0.24-0.54, P <0.0001). The authors of both reports acknowledged the limita tions of populationbased retrospective studies, such as treatment selection bias and the inability to account for unmeasured factors 44, 45 . Furthermore, these reports described largely over lapping populations (subtle vari ation in inclusion criteria accounted for minor popula tion differences), and treated men comprised <5% of the study population. Nonetheless, consistent findings were obtained using two different sophisticated analyses. Of note, patients who underwent external beam radiation therapy (EBRT) were excluded from these studies owing to the lack of organsitespecific coding for EBRT in SEER data.
Data from Gratzke et al. 46 subsequently analysed 1,538 patients in the Munich Cancer Registry with inci dent metastatic prostate cancer between 1998 and 2010. In total, 74 men (5%) underwent prostatectomy and demonstrated 55% overall survival at 5 years, compared with 21% in the no prostatectomy group (P <0.01). The nonsurgical group consisted of 635 men (41.3%) who underwent primary ADT, 389 men (25.3%) treated with radiation, and 440 men (28.6%) who underwent other treatment. Whether the study distinguished between definitive or palliative treatment in the radiation therapy group was not reported; this omission might explain why outcomes in the radiation group mirrored the primary ADT and other treatment groups, and why radi ation therapy was not considered in the same Population-based, n = 8,185, median follow-up period: 16 months
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• 0.43 (P = 0.015) MVA includes: ECOG status, site of metastasis ADT, androgen deprivation therapy; aHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; BT, brachytherapy; CCI, Charlson comorbidity index; CRR, competing risk regression; CRT, conformal radiation therapy; CSM, cancer-specific mortality; CSS, cancer-specific survival; CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; FDG, fluorodeoxyglucose; IMRT, intensity-modulated radiation therapy; LN, lymph node; MRI, magnetic resonance imaging; MVA, multivariable analysis; NLT, no local treatment; NR, not reported; NS, not specified; OM, overall mortality; OS, overall survival; PCSM, prostate-cancer-specific mortality; RP, radical prostatectomy; RT, radiation therapy; SHR, subhazard ratio. *In cases of unspecified time frame, values refer to proportion experiencing outcome during total follow-up period.
manner as surgery. Acknowledging these considerable limitations, these data demonstrated a reproducible benefit of surgery, albeit in a highly selected sample of the population. In a subsequent report, Satkunasivam and col leagues 47 used a unique approach to address some of the limitations of previous studies. By linking the SEER database to Medicare, the authors were able to account for comorbidities and ADT use in the study population. Furthermore, they assigned a threshold of ≤15 radio therapy claims as consistent with palliative treatment, and were, therefore, able to assess the effect of localized, nonpalliative intensity modulated radiation therapy (IMRT) and conformal radiation therapy (CRT) [51] [52] [53] . At baseline, the radical prostatectomy and IMRT groups were younger and had lower serum PSA levels, Gleason scores, and American Joint Committee on Cancer 54 T and N stage tumours than the no local treatment and CRT groups (all P <0.001). Conversely, the radical pros tatectomy and IMRT groups were less likely to receive bone radiation (radical prostatectomy 0%, IMRT 2%, CRT 7%, no local therapy 11%, P = 0.005) or ADT (rad ical prostatectomy 43%, IMRT 66%, CRT 88%, no local therapy 70%, P <0.001) in the 6month period following diagnosis. On multivariable analysis including socio demographic factors, tumour characteristics, Charlson comorbidity index, use of ADT, and bone radiation within 6 months of diagnosis, the adjusted hazard ratios for PCSM were 0.48 (95% CI 0.27-0.85, P = 0.01) for rad ical prostatectomy, 0.38 (95% CI 0.24-0.61, P <0.001) for IMRT, and 0.85 (95% CI 0.64-1.14, P = 0.3) for CRT.
Additionally, Heidenreich and colleagues 48 reported the first casecontrol study to examine prostatectomy in selected men with metastatic disease. Their study was limited to 23 men with ≤3 lesions on bone scan, no vis ceral or extended lymph node metastases, and response to ADT (PSA nadir <1.0 ng/ml after 6 months of ADT). They identified a control cohort of 38 men with simi lar clinical and pathological characteristics. However, it should be noted that only 26 of the 38 control patients (68%) responded to ADT. Both groups were followed up for evidence of castration resistance (defined as bio chemical progression in the presence of castrate serum testosterone levels (≤50 ng/dl)), clinical progression (defined as new symptoms due to local progression or lymphonodular or systemic metastases), and sur vival. After a median followup period of 40.6 months in the radical prostatectomy group and 44.0 months in the nonradicalprostatectomy group (P >0.05), men treated with radical prostatectomy demonstrated signifi cantly increased time to castration resistance (median 40 months versus 29 months, P = 0.014) and freedom from clinical progression (median 38.6 months versus 26.5 months, P = 0.032). The crude proportion of overall survival (91.3% versus 78.9%, P = 0.048) was similarly improved in the radical prostatectomy cohort. The pro portion of cancerspecific survival (95.6% versus 84.2%, P = 0.043) was improved with radical prostatectomy, although the median cancerspecific survival was not (47.0 versus 40.5 months, P >0.05). Given that all sur gical patients were responsive to ADT, why the control group was not limited to the 26 ADTresponsive men is unclear. This additional uniformity between cases and controls could have limited the effect of selection bias, which is a substantial limitation of such reports.
Finally, Cho et al. 49 performed a casecontrol compar ison in 140 men with varying extents of metastatic dis ease; 38 men underwent prostate radiotherapy, 39 men underwent palliative radiotherapy, and 63 men did not undergo radiotherapy. Over a median followup period of 34.0 months (range 1.7-108.8 months), the 3year overall survival was 69% in those who had received prostate radiotherapy and 43% in the other groups (P = 0.004). Similarly, 3year biochemicalfailurefree survival was improved in the prostate radiation cohort (52% versus 16%, P = 0.002). The authors did observe Grade 3 thrombocytopenia in four patients (11%) and Grade 3 leukocytopenia in three patients (8%) but did not report any Grade 3 genitourinary complications.
Metastasis-directed therapy
Five studies describing metastasisdirected therapy can be found in the literature [28] [29] [30] [31] 55 (TABLE 3) . Muacevic et al. 55 treated a total of 40 patients with one or two bony metas tases using stereotactic body radiation (SBRT), 34 (85%) of whom were asymptomatic on presentation. Patients were considered for treatment regardless of their initial response to ADT. The authors observed local control (defined as lack of documented tumour growth on MRI and lack of increased tracer uptake on choline PET-CT compared with pretreatment imaging) in 95.5% of men at 2 years from treatment, including 27 men (68%) treated with ADT during the followup period. Adverse effects were relatively minor, including mild nausea in five men (12.5%) and a silent rib fracture in one (2.5%) patient. Ahmed et al. 28 subsequently observed similar results using SBRT in a cohort of 17 men. In this study, the authors treated one liver lesion and one lymph node lesion in addition to 19 bone metastases. They observed 100% local control (defined as lack of tumour progres sion within the planning target volume) among evalu able lesions at a median followup point of 6 months, and nine (53%) patients reached an undetectable serum PSA. Interestingly, over half of the men with hormone refractory disease had either reached an undetectab le PSA level or had persistently declining PSA at the time of analysis. These authors measured safety according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 56 . After treatment of 21 lesions, the authors reported two (9.5%) Grade 1 and two (9.5%) Grade 2 events, with no Grade 3 or late toxicities observed.
In a cohort of 50 men, Schick and colleagues 30 used EBRT to treat distant and/or regional lymph nodes in 33 men (66%), bone in 15 men (30%), lung in one man (2%), and both bone and lung in one man (2%). After a median followup duration of 31 months, they reported 3year biochemicalrecurrencefree survival of 54.5%, clinicalfailure (development of new metastases)free survival of 58.6%, and overall survival of 92%. Similar to previous studies, they observed no Grade 3 toxic effects. Berkovic et al. 29 treated 24 men with up to three bone or lymph node metastases using SBRT. Again, 2year rates of local control were 100%; clinical progression (detection of local progression or distant disease at reassessment)free survival was 42%. Even after 11 patients (46%) underwent a second treatment and three (12.5%) underwent a third, adverse effects were limited to Grade 2 gastrointestinal (8%) and genitourinary (6%) toxicities, with no Grade 3 toxicities. Importantly, the authors report median ADTfree survival of 38 months after treatment. In 2014, Decaestecker et al. 31 described the treatment of 50 men with lymph node (54%), bone (44%), or vis ceral (2%) metastases with SBRT. After median followup period of 2 years, local control (defined as tumour pro gression within the irradiated planning target volume) was observed in 100% of the cohort. Progressionfree survival rates at 1 year and 2 years after treatment were 64% and 35%, respectively. Meanwhile, median delay to ADT was 25 months, with 82% of men avoiding ADT at 1 year from treatment. Again, toxicity was limited to Grade 1 (14%) and Grade 2 (6%) events. A pooled ana lysis of data from these and other cohorts confirmed no Grade 3 toxicity and improved progressionfree survival in the treated population 32 .
Imaging of oligometastatic prostate cancer
Current clinical practice is to define the extent of meta static prostate cancer with crosssectional imaging (CT and/or MRI) as well as 99m Tcmethylene diphosphonate planar or single photon emission tomography (SPECT) bone scan 57 . In an attempt to improve the lower limit of prostate cancer detection -and in doing so refine the definition of oligometastatic prostate cancer -the past few years have witnessed a flurry of research into novel PET radiotracers targeting lesions of the bone and soft tissue. 18 Fsodium fluoride (Na 18 F) is perhaps the most widely available PET radiotracer for imaging prostate cancer. Like 99m Tcmethylene diphosphonate, Na 18 F homes to areas of bone remodelling, enabling the detec tion of osteoblastic metastases. Given that PET offers improved spatial resolution over planar and SPECT imaging, it is not surprising that Na 18 F PET-CT has consistently been shown to offer superior sensitivity for detecting osseous metastases relative to conventional bone scan [58] [59] [60] . However, one limitation of Na 18 F PET-CT is the continued reliance on CT and/or MRI to evaluate for soft tissue metastases.
PET-CT with radiotracers that directly target cancer cells offers a more efficient and potentially sensitive approach for prostate cancer imaging. Radiotracers that have received attention for this purpose include 11 Ccholine, 18 Ffluoroethylcholine, 18 Case series, n = 24, 29 lesions, median followup period: 24 months
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The literature regarding these emerging tests for prostate cancer imaging is very promising, but remains immature at this stage. Accordingly, current guide lines and recommendations remain based on con ventional imaging modalities. Given the potential for enhanced sensitivity using PET-CT, molecularly targeted imaging will likely have an increasing role in defining the oligometastatic state as well as aiding in metastasisdirected therapy.
Considering the literature
The rationale for aggressive treatment An aggressive approach to treating limited meta static disease could prove beneficial. Indeed, treat ment of the primary tumour seems to reduce the need for palliative interventions of locally advanced disease 48, 64 . Furthermore, early local therapy might delay the initiation of systemic therapies such as ADT, which have a substantial effect on quality of life 65 . Undoubtedly, the ultimate goal of such an approach is to improve survival.
Several clinically and biologically plausible mechan isms could explain how aggressive local and metastasis directed therapies could improve survival of men with oligometastatic prostate cancer. Improved clinical out comes observed with local treatment of other primary cancers in the metastatic setting [66] [67] [68] [69] mean that tumour debulking could derive similar benefits in prostate can cer by prolonging the duration to a fatal tumour burden. With increased understanding of the communicating ecosystem of metastatic prostate cancer 70, 71 , treatment of the primary tumour might also eliminate a critical site of interaction and support of metastases [72] [73] [74] . Other studies have discussed the potential role of the primary tumour in host immunosuppression and in creating a favourable hormonal milieu for cancer growth [75] [76] [77] . Therapeutics targeting the anticancer immune response have shown great promise, particularly in melanoma, as well as bladder, lung, and other malig nancies [78] [79] [80] [81] . One phase III trial of ipilimumab failed to demonstrate an overall survival benefit in men with metastatic prostate cancer, but improvements in progres sionfree survival and overall diseasefree survival were observed in men with lower tumour burden 82 . This out come suggests that immunotherapies could be effective in the oligometastatic state, before disease burden is sub stantial enough to evade augmented anticancer immune surveillance. Accordingly, multiple trials have been opened and others are being planned to test immuno therapeutics in the oligometastatic setting. These studies include actively recruiting trials combining immuno therapy with treatment of the primary tumour, such as NCT02489357 and NCT02020070 (REFS 35, 41) .
Despite great promise, no clear evidence of improved survival based on an aggressive approach is currently available 83 , and can only be definitively obtained in the setting of randomized trials. This obstacle is aug mented by the lack of a standard definition for oligo metastatic prostate cancer, which must be properly set out before we can examine the effects of therapy in the oligometastatic state.
Defining the oligometastatic state Based on earlier work of Soloway and colleagues 43 , Singh and et al. 84 investigated survival as a function of the number of metastatic lesions observed per patient, finding that men with ≤5 lesions had similar survival to those with no metastases and significantly better survival than those with >5 lesions (P = 0.02). A number of stud ies subsequently adopted a definition of oligo metastases based on this threshold 27, 28 , and further studies have con firmed the role of lesion count in clinical outcomes 85 . In addition to lesion count, the site of metastasis has emerged as a substantial contributor to prognosis 86 . Review of published reports and active clinical trials confirms wide variability in how oligometastatic pros tate cancer has been defined: six studies (38%) impose a limit of three metastases 29, 31, 32, 36, 38, 42 and five (31%) use a limit of five metastases 27, 28, 34, 39, 40 . Three studies (19%) include up to four metastases 30, 35, 37 , one (6%) up to 10 metastases 41 , and one (6%) does not strictly define an upper limit of lesions 33 . Eight of the 16 reports speci fied sites of metastasis that were considered in defining oligometastatic disease.
Indeed, lesion count and location do seem to affect clinical outcomes and, therefore, a clinical definition of metastasis such as that proposed by Rubin and col leagues 12 , whereby metastatic disease is designated as either a solitary metastasis (M1), two to five metas tases (M2), polymetastases of a single organ (M3), or polymetastases of multiple organs (M4), seems logical. Of course, such distinctions are limited by several fac tors, most notably the sensitivity of imaging for detec tion. A more accurate definition would incorporate tumourspecific data to also provide a molecular basis for the observed phenotype. For example, Lussier and colleagues 11 identified tumour microRNA expression patterns that can potentially distinguish cancers likely to remain in a stable, limited metastatic state (≤5 lesions) from those that will imminently progress to polymeta static disease 11 . The authors confirmed their findings in animal models and demonstrated that one classifier -microRNA200c -was capable of converting stable oligometastatic disease to a progressive poly metastatic state in xenograft models. Although additional testing and validation are undoubtedly necessary, such research represents great progress toward understand ing the vastly different clinical states encountered 87, 88 . As the authors suggest, the application of these meth ods could greatly improve patient selection for specific treatment pathways 89 . Ultimately, we must consider what lesion counts and genomic classifiers are telling us -the oligometa static state might simply be one part of an inevitable progression toward polymetastases, or, in some cases, perhaps it could represent a cancer's final destination, whereby directed treatment of extant disease sites could prove curative. On a population level, the answer seems to encompass each of these possibilities. Indeed, some lesions will grow and metastasize to widespread dis ease over a short interval; others will do so gradually, such that the oligometastatic phenotype stably persists for months or years and is a clinically relevant state itself. Still others seem to lack the capacity to do so at all, such that a limited metastatic state represents its greatest potential for progression. The ability to discern these differences provides the potential to optimize the therapeutic approach for each patient.
Site-specific therapies
Regarding localized therapy. Overall, the data consider ing the use of local consolidative therapy for metastatic prostate cancer are quite limited. SEERbased studies, for example, lack data regarding the use of additional therapies such as chemohormonal therapy or sitespecific EBRT, as well as patient comorbidities and performance status 44, 45 . Such factors undoubtedly affect patient sur vival. By linking SEER with Medicare data, Satkunasivam et al. 47 were able to mitigate some of these limitations; however, as a consequence their study was limited to men 65 years and older, resulting in a poorly generaliz able analysis, particularly as an aggressive management approach might be more reasonable in younger men.
Acknowledging these limitations, the majority of findings suggest that local therapy could indeed improve survival in a selected group of patients. Interestingly, although the extent of metastatic disease consistently predicted cancerspecific mortality, the beneficial effect of local treatment was observed across all M stages. This observation raises the possibility that local treat ment could benefit men in various metastatic states, and that overall patient health and comorbidity should be considered when using an aggressive approach 90 . Conversely, several studies have demonstrated that the benefit of local treatment is directly tied to the risk of cancerspecific mortality 91, 92 . The reality is that optimal patient selection is likely to be based on a balance of both patient and disease characteristics.
Importantly, initial data suggest that prostatectomy can be performed safely in the metastatic setting. Heidenreich et al. 48 reported no Clavien Grade IV or V complica tions in men treated with radical prostatectomy, and the proportion experiencing grades I-III complications was similar to or better than gradespecific controls. Furthermore, palliative intervention was required in 11 of 38 (28.9%) control patients, compared with zero men who underwent radical prostatectomy, and 21 (91.3%) patients reported postoperative continence, requiring either zero or one pad per day. A retrospective multi institutional analysis of radical prostatectomy in the set ting of distant metastases was similarly encouraging 93 . The overall rates of complications, readmission, and reoperation were 20.8%, 3.8%, and 1.9%, respectively, versus 19.4%, 3.0%, and 2.3%, respectively in open cases performed for standard indications 94 .
Regarding metastasis-directed therapy. With increased adoption of local ablative techniques, most notably SBRT, increasing data now describe patient outcomes after metastasisdirected therapies [28] [29] [30] [31] 55 . Although cancerspecific survival and overall survival outcomes are limited by short followup intervals, two undenia ble trends can be identified in the available data. First, use of SBRT for treatment of metastatic lesions seems to be very safe. In a cohort of 141 men included in four studies using CTCAEbased reporting of adverse effects, zero (0%) Grade 3 toxicities were reported. Lowgrade toxicity was generally limited to gastrointestinal effects, such as nausea, and was consistently observed in <20% of treated patients. Second, local control rates were con sistently very high, including ≥95.5% in the four studies reporting this outcome (median followup duration 6-31 months). Establishing a minimal likelihood of substantial adverse effects is crucial when considering widespread use of these techniques. Although a cornerstone of treating metastatic pros tate cancer, ADT is associated with several deleterious adverse effects and, in some patients, might decrease overall life expectancy 65, 95 . These effects raise the ques tion of whether consolidative treatments can prevent or delay the use of ADT. Given varying baseline rates of ADT use and varying indications for initiating ADT during followup monitoring, quantifying an average effect of directed therapies is difficult. Berkovic et al. 29 and Decaestecker et al. 29, 31 reported median ADTfree survival of 38 months and 25 months, respectively, after treatment with SBRT. Three other studies calculated the proportion of treated men who ever used ADT, with val ues ranging from 68% to 98% 28, 30, 55 . Furthermore, sev eral studies reported variably defined outcomes, such as clinical progression or biochemicalprogressionfree survival. These rates were inconsistently reported and ranged widely across studies, again leading to difficulty in deriving a general trend in outcomes. Finally, it must be acknowledged that definitive conclusions regarding more meaningful clinical outcomes cannot be derived from surrogate measures such as those reported, and these studies notably lack a comparison arm. More definitive data will become available after the comple tion and reporting of prospective randomized studies (TABLE 1) such as the Belgian STOMP trial 96 and the Baltimore ORIOLE trial 42 (FIG. 2) , which primarily aims to assess clinical progression in men randomized to receive SBRT versus observation. Secondary end points include local control, ADTfree survival, toxicity, and qualityoflife outcomes.
We would encourage future retrospective and pro spective studies to clearly distinguish the number of men using ADT at baseline, and to provide median and 1year ADTfree survival in those who are not. We pro pose that future studies define clinical progression as the detection of a new metastatic lesion or the occurrence of a clinically significant event (such as pain onset or fracture) in a previously detected stable lesion. Given the limited time course over which such events occur, it would be reasonable to share median, 1year, and 3year values for these outcomes.
Future directions and recommendations
Existing data suggest that local and metastasisdirected therapies are safe in men with metastatic prostate cancer. Whether we should take an aggressive approach to meta static disease simply because it is available and whether this approach actually helps patients still needs address ing. Only retrospective data exist in this setting, and few of these studies provide an appropriate control group for comparison. Thus, the reality is that we are only just beginning to answer this question. In light of this limit ation, we make the following recommendations for con sidering an aggressive treatment approach for men with known metastatic disease.
As in other settings, only those patients likely to suffer mortality or substantial morbidity due to their disease should be considered for aggressive treatment, which should only be offered in the setting of an institutionalreviewboardapproved clinical trial or pro spective registry. Patients must be fully informed of the potential risks and benefits associated with an aggressive approach; specifically, they must be made aware that data from appropriately conducted studies to demonstrate pro longed survival as a result of treatment is lacking. Men who do undergo treatment should be assessed and treated in a multidisciplinary setting including medical oncology, radiation oncology, and urology. Clinicians managing such patients should consider establishing a prostate can cer multidisciplinary clinic if not already present at their institution 97 . Finally, establishment of an institutional biorepository for banking of serum, urine, stool, and tissue samples should be considered -only with the commit ted and coordinated efforts of the entire healthcare team will we find answers to the many questions that remain.
Conclusions
In the future, oligometastatic prostate cancer is likely to be defined based on genomic and biological features in addition to pertinent clinical criteria. For now, a defi nition based on up to five detectable lesions is widely employed and is reasonable for use. Available data suggest that local therapies such as prostatectomy and radiotherapy can be performed safely in the presence of metastatic disease and might prevent the need for future palliative treatments. Similarly, metastasisdirected therapies such as SBRT carry a low risk of toxic effects and provide excellent local control. At this time, insuf ficient data are available to draw conclusions regarding the effect of aggressive therapies on overall or cancer specific survival. Prospective, wellcontrolled trials are necessary and should aim to report outcomes in a consistent and systematic manner.
